Advertisement
Even after ending the week on a red signal, Xilio Therapeutics Inc closed at 1.14 USD as of 7:58 PM GMT-5 on February 14, reflecting a significant increase of +0.47 USD or 70.12% over the past five days. This dramatic rise was a result of the announcement regarding the company’s collaboration with AbbVie to develop cancer treatments.
During the session, the stock reached a high of 1.30 USD and a low of 1.00 USD, indicating considerable price volatility. Xilio opened the day at 1.29 USD but faced some selling pressure.
In after-hours trading, the stock dipped slightly to 1.12 USD, a decline of 1.75% or -0.020 USD. With a market capitalization of 5.25 crore, the biotech company tries to gain its strength in Wall Street.
Disclaimer: This article is for informational purposes only and does not constitute any financial advice.